FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2046221853> ?p ?o ?g. }

• W2046221853 endingPage "602" @default.
• W2046221853 startingPage "598" @default.
• W2046221853 abstract "Autoimmune hemolytic anemia (AIHA) is a well-known complication of chronic lymphocytic leukemia (CLL). In recent years the anti-CD20 monoclonal antibody rituximab has been used for the therapy of steroid-refractory AIHA and autoimmune thrombocytopenia, either idiopathic or in association with CLL. We report the results of rituximab treatment for 14 patients suffering from CLL-associated AIHA. They developed a direct antiglobulin test positive AIHA at a mean time of 47 months (range 0–135 months) from the diagnosis of CLL. In 3 cases AIHA was diagnosed at the same time as CLL. Only 1 patient had fludarabine-related AIHA. All patients received steroids as first-line treatment. At a mean time of 46 days (range 1–210 days) from the diagnosis of AIHA all patients received rituximab at a dosage of 375 mg/m2/weekly for 4 weeks. All patients except 3 (2 died of cardiac failure or sepsis soon after the third cycle and 1 HCV-positive patient experienced a rise in serum amino transferases) completed the scheduled four programmed cycles. First injection side effects of rituximab were minimal. All but 2 patients showed an increase in hemoglobin levels in response to rituximab (mean value 3.6 g/dl; range 0.7–10 g/dl) and a reduction in the absolute lymphocyte count and lymph nodes and spleen volume. Nine patients required packed red cell transfusions before starting rituximab; 5 no longer needed transfusions just after the second cycle and another patient after the fourth cycle. Three patients (22%) were considered to fully respond and 7 (50%) only responded partially. At a mean follow-up of 17 months, 8 patients were still alive, 6 of them transfusion-free. Our results prove that the anti-CD20 monoclonal antibody is an effective and well-tolerated alternative treatment for CLL-associated AIHA. Am. J. Hematol. 81:598–602, 2006. © 2006 Wiley-Liss, Inc." @default.
• W2046221853 created "2016-06-24" @default.
• W2046221853 creator A5002073636 @default.
• W2046221853 creator A5011614506 @default.
• W2046221853 creator A5029439323 @default.
• W2046221853 creator A5030806032 @default.
• W2046221853 creator A5033029228 @default.
• W2046221853 creator A5035514953 @default.
• W2046221853 creator A5040824984 @default.
• W2046221853 creator A5042609656 @default.
• W2046221853 creator A5048142810 @default.
• W2046221853 creator A5062313667 @default.
• W2046221853 creator A5063235996 @default.
• W2046221853 creator A5076571467 @default.
• W2046221853 creator A5085216234 @default.
• W2046221853 date "2006-01-01" @default.
• W2046221853 modified "2023-10-01" @default.
• W2046221853 title "Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia" @default.
• W2046221853 cites W137167786 @default.
• W2046221853 cites W1499296962 @default.
• W2046221853 cites W1903703315 @default.
• W2046221853 cites W1998623418 @default.
• W2046221853 cites W2004505087 @default.
• W2046221853 cites W2005090731 @default.
• W2046221853 cites W2008472399 @default.
• W2046221853 cites W2027755592 @default.
• W2046221853 cites W2028453745 @default.
• W2046221853 cites W2041498582 @default.
• W2046221853 cites W2066015434 @default.
• W2046221853 cites W2069452720 @default.
• W2046221853 cites W2087225207 @default.
• W2046221853 cites W2133315774 @default.
• W2046221853 cites W2165505664 @default.
• W2046221853 cites W2165507228 @default.
• W2046221853 cites W2178741645 @default.
• W2046221853 cites W2323490326 @default.
• W2046221853 cites W4246675764 @default.
• W2046221853 cites W60759546 @default.
• W2046221853 doi "https://doi.org/10.1002/ajh.20665" @default.
• W2046221853 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16823816" @default.
• W2046221853 hasPublicationYear "2006" @default.
• W2046221853 type Work @default.
• W2046221853 sameAs 2046221853 @default.
• W2046221853 citedByCount "96" @default.
• W2046221853 countsByYear W20462218532012 @default.
• W2046221853 countsByYear W20462218532013 @default.
• W2046221853 countsByYear W20462218532014 @default.
• W2046221853 countsByYear W20462218532015 @default.
• W2046221853 countsByYear W20462218532016 @default.
• W2046221853 countsByYear W20462218532017 @default.
• W2046221853 countsByYear W20462218532018 @default.
• W2046221853 countsByYear W20462218532019 @default.
• W2046221853 countsByYear W20462218532020 @default.
• W2046221853 countsByYear W20462218532021 @default.
• W2046221853 countsByYear W20462218532022 @default.
• W2046221853 countsByYear W20462218532023 @default.
• W2046221853 crossrefType "journal-article" @default.
• W2046221853 hasAuthorship W2046221853A5002073636 @default.
• W2046221853 hasAuthorship W2046221853A5011614506 @default.
• W2046221853 hasAuthorship W2046221853A5029439323 @default.
• W2046221853 hasAuthorship W2046221853A5030806032 @default.
• W2046221853 hasAuthorship W2046221853A5033029228 @default.
• W2046221853 hasAuthorship W2046221853A5035514953 @default.
• W2046221853 hasAuthorship W2046221853A5040824984 @default.
• W2046221853 hasAuthorship W2046221853A5042609656 @default.
• W2046221853 hasAuthorship W2046221853A5048142810 @default.
• W2046221853 hasAuthorship W2046221853A5062313667 @default.
• W2046221853 hasAuthorship W2046221853A5063235996 @default.
• W2046221853 hasAuthorship W2046221853A5076571467 @default.
• W2046221853 hasAuthorship W2046221853A5085216234 @default.
• W2046221853 hasConcept C126322002 @default.
• W2046221853 hasConcept C18031839 @default.
• W2046221853 hasConcept C203014093 @default.
• W2046221853 hasConcept C2776694085 @default.
• W2046221853 hasConcept C2776755627 @default.
• W2046221853 hasConcept C2777385706 @default.
• W2046221853 hasConcept C2777938653 @default.
• W2046221853 hasConcept C2778248108 @default.
• W2046221853 hasConcept C2778461978 @default.
• W2046221853 hasConcept C2778714382 @default.
• W2046221853 hasConcept C2779263901 @default.
• W2046221853 hasConcept C2779338263 @default.
• W2046221853 hasConcept C2780653079 @default.
• W2046221853 hasConcept C71924100 @default.
• W2046221853 hasConcept C90924648 @default.
• W2046221853 hasConceptScore W2046221853C126322002 @default.
• W2046221853 hasConceptScore W2046221853C18031839 @default.
• W2046221853 hasConceptScore W2046221853C203014093 @default.
• W2046221853 hasConceptScore W2046221853C2776694085 @default.
• W2046221853 hasConceptScore W2046221853C2776755627 @default.
• W2046221853 hasConceptScore W2046221853C2777385706 @default.
• W2046221853 hasConceptScore W2046221853C2777938653 @default.
• W2046221853 hasConceptScore W2046221853C2778248108 @default.
• W2046221853 hasConceptScore W2046221853C2778461978 @default.
• W2046221853 hasConceptScore W2046221853C2778714382 @default.
• W2046221853 hasConceptScore W2046221853C2779263901 @default.
• W2046221853 hasConceptScore W2046221853C2779338263 @default.
• W2046221853 hasConceptScore W2046221853C2780653079 @default.

• next